JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 14 citations · 24 references
Life SciencesImmunologyInfectious DiseasesHepatologyMolecular VirologyVirologyAntiretroviral TherapyAntiviral TherapyInterferon-based TherapyLiver DiseaseTreatment DurationViral HepatitisBaseline Hiv TestingHepatitis C InfectionHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyInterferon ProductionLinear RegressionViral KineticsViral Load Assessment
BACKGROUND: Reports are mixed as to whether highly active antiretroviral therapy (HAART) increases liver transaminase levels or hepatitis C virus (HCV) titers in HIV/HCV-coinfected individuals. It is hypothesized that increases in HCV RNA titers may result from changes in endogenous interferon-alpha (IFN-alpha) production. METHODS: HIV/HCV-coinfected patients receiving HAART were tested at baseline, 1, 2, 3, 6, and 9 months for liver transaminase levels, HIV and HCV viral loads, and IFN-alpha. Linear regression analysis was used to determine the effect of HAART on liver transaminase levels, HCV viral load, and IFN-alpha. RESULTS: Initiating HAART did not increase liver transaminase levels in majority of cases. In patients (n = 30) with baseline HIV titer >10,000 copies/mL, HCV titers increased 0.69 log10 and IFN-alpha decreased -0.96 log10 during HAART, in association with a > or =0.5 log10 decrease in HIV titer. As HIV titers reached their nadir approximately 4 months after initiation of HAART, HCV titers remained 0.54 log10 and IFN-alpha -0.71 log10 above and below baseline levels, respectively. HCV titers and IFN-alpha levels did not change from baseline in patients with baseline HIV titer < or =10,000 copies/mL. CONCLUSIONS: Coinfected patients did not have evidence of hepatoxicity HAART. In patients with baseline HIV titer >10,000 copies/mL, suppression of HIV replication by HAART was associated with an increase in HCV titer and a decrease in endogenous IFN-alpha levels.
24
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Gary L. Davis, Luis A. Balart, Eugene R. Schiff et al. · New England Journal of Medicine · 1989 · 1.7K citations
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C
Adrian M. Di Bisceglie, Paul Martin, Chris Kassianides et al. · New England Journal of Medicine · 1989 · 1.2K citations
Kenneth E. Sherman, Susan D. Rouster, Raymond T. Chung et al. · Clinical Infectious Diseases · 2002 · 732 citations · Full text